Meeting of the Board of Directors is scheduled to be held on May 22, 2025 to consider and approve Audited Financial Results of the Company and recommendation of Dividend on equity shares ....
LINCOLN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lincoln Pharmaceuticals has informed the stock exchanges that its Board of Directors will meet on May 22, 2025 to consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2025. The Board will also consider recommending a dividend on equity shares, though the announcement makes it clear this is optional ('if any'). The trading window for dealing in company securities, already closed since April 1, 2025, will reopen 48 hours after the results are made public. No financial numbers or outcomes are disclosed at this stage as this is only a pre-meeting intimation.
This is a routine pre-results announcement and carries no direct impact on the stock. Investors should watch the May 22 outcome for actual FY25 numbers and any dividend declaration, which could influence share price and near-term returns.